A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors
Latest Information Update: 09 Dec 2025
At a glance
- Drugs DB 1324 (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors Duality Biologics
Most Recent Events
- 09 Dec 2025 New trial record